Seltorexant
- Generic Name
- Seltorexant
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H22FN7O
- CAS Number
- 1452539-75-1
- Unique Ingredient Identifier
- AIS8N3O50B
- Background
Seltorexant is under investigation in clinical trial NCT03494907 (A Study to Evaluate the Effects of Single-dose Seltorexant on Electrocardiogram Intervals in Healthy Adult Participants).
- Associated Conditions
- -
- Associated Therapies
- -
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- Conditions
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 752
- Registration Number
- NCT06559306
- Locations
- πΊπΈ
Axiom Research, Colton, California, United States
πΊπΈExcell Research Inc, Oceanside, California, United States
πΊπΈProspective Research Innovations Inc, Rancho Cucamonga, California, United States
A Study of Seltorexant in Participants With Probable Alzheimer's Disease
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 88
- Registration Number
- NCT05307692
- Locations
- πΊπΈ
Allied Biomedical Research Institute (ABRI), Inc, Miami, Florida, United States
πΊπΈQuantix Research, Miami, Florida, United States
πΊπΈEntrust Clinical Research, Miami, Florida, United States
A Study of JNJ-42847922 (Seltorexant) in Healthy Participants
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 10
- Registration Number
- NCT05236868
- Locations
- π³π±
PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen, Netherlands
A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem
- Conditions
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 127
- Registration Number
- NCT05106153
- Locations
- πΊπΈ
Altasciences Inc., Overland Park, Kansas, United States
A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants
- First Posted Date
- 2021-07-13
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 24
- Registration Number
- NCT04960124
- Locations
- π©πͺ
APEX GmbH, Munchen, Germany
π©πͺCRS Clinical Research Services Kiel GmbH, Kiel, Germany
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 31
- Registration Number
- NCT04951609
- Locations
- πΊπΈ
CincyScience, West Chester, Ohio, United States
πΊπΈSouthwest Autism Research and Resource Center, Phoenix, Arizona, United States
πΊπΈYale University, New Haven, Connecticut, United States
A Study to Evaluate the Effect of Renal Impairment on JNJ-42847922 in Adult Participants
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2023-02-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 24
- Registration Number
- NCT04616677
- Locations
- πΊπΈ
AMR New Orleans, Formerly New Orleans Center for Clinical Research - New Orleans, an AMR company, Knoxville, Tennessee, United States
πΊπΈOrlando Clinical Research Center, Orlando, Florida, United States
A Study of Seltorexant in Healthy Participants
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2021-04-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 69
- Registration Number
- NCT04553042
- Locations
- πΊπΈ
PRA Health Sciences, Salt Lake City, Utah, United States
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 588
- Registration Number
- NCT04533529
- Locations
- π¨πΏ
Neuroterapie KH S R O, Kutna Hora, Czechia
π¨πΏA Shine S R O, Plzen, Czechia
π¨πΏMedical Services Prague S R O, Praha 6, Czechia
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 212
- Registration Number
- NCT04532749
- Locations
- π¦π·
STAT Research S A, Ciudad Autonoma de Buenos Aires, Argentina
πΊπΈAltea Research Institute, Phoenix, Arizona, United States
πΊπΈPreferred Research Partners, Little Rock, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.